KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Accumulated Expenses (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed Accumulated Expenses for 8 consecutive years, with $19.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses rose 282.3% year-over-year to $19.2 million, compared with a TTM value of $19.2 million through Dec 2025, up 282.3%, and an annual FY2025 reading of $19.2 million, up 282.3% over the prior year.
  • Accumulated Expenses was $19.2 million for Q4 2025 at Esperion Therapeutics, up from $1.6 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $34.5 million in Q3 2021 and bottomed at $1.2 million in Q2 2025.
  • Average Accumulated Expenses over 5 years is $14.4 million, with a median of $8.2 million recorded in 2023.
  • The sharpest move saw Accumulated Expenses soared 443.78% in 2023, then tumbled 94.81% in 2025.
  • Year by year, Accumulated Expenses stood at $7.0 million in 2021, then fell by 22.63% to $5.4 million in 2022, then skyrocketed by 360.71% to $25.0 million in 2023, then tumbled by 79.86% to $5.0 million in 2024, then surged by 282.3% to $19.2 million in 2025.
  • Business Quant data shows Accumulated Expenses for ESPR at $19.2 million in Q4 2025, $1.6 million in Q3 2025, and $1.2 million in Q2 2025.